Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05168397
Other study ID # RV4857A202092
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 16, 2020
Est. completion date November 9, 2020

Study information

Verified date December 2021
Source Pierre Fabre Dermo Cosmetique
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57 days of use and its efficacy against recurrence of acne lesions post-sun exposure.


Description:

This is a monocentric study on adults and adolescents with acne prone skin on the face. This open-labelled study aim first to assess the dermatological and ophthalmological tolerance of the investigational sunscreen product RV4857A formula CD2110 after 28 days and, dermatological tolerance after 57 days of at least a twice daily on the study areas, under normal conditions of use, on 40 subjects intending to have a minimum of 10 days per month of sun exposure duration ≥ 1h, in the time slot 11am-4pm and intending to have a minimum of 4 swimming sessions (sea or swimming pool) during at least the first month of the study. Secondary objectives : - To assess the anti-imperfection efficacy of the product during the summer - To assess the "non" rebound effect (non recurrence of acne) one month after stopping the application of the sunscreen and without any sun exposure at D85 (difference between D85 and D0) - To evaluate the impact on Quality of Life of subjects through CADI and DLQI questionnaires (or CDLQI questionnaire for adolescent from 12 to 16 years-old) completed at baseline, D29 and D57 The study includes 4 visits : - Visit 1: Inclusion visit (D1) - Visit 2: Intermediate visit (D29) - Visit 3: Intermediate visit "end of summer" (D57), a Stop the application of the sunscreen product (and stop sun exposure) between Visit 3 and the end of the study Visit 4: End of study visit in autumn (D85) The theoretical study duration for each subject will be 85 days with at least 57 days of product use. The study interest areas are Face and Neck.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date November 9, 2020
Est. primary completion date November 9, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 40 Years
Eligibility Inclusion Criteria: 1. Related to the population: - Females and/or males (with at least 25% of male) - Age: adults from 18 to 40 years old and adolescent from 12 to 17 years old (33% to 50% of the total population) - Considered "healthy subject" by the Investigator - Being of Phototype I to IV - Subject with combination to oily skin - Subject who foresees sun exposure during the first 2 months of the study - Subjects must be registered with health social security or health social insurance (if required by national regulations) - Subject and/or parent(s)/legal representative(s) who have signed his/her/their written informed consent for his/her participation in the study (or his/her/their child participation in the study) and a photograph authorization - For woman of childbearing potential: committing herself to use effective contraceptive method since at least 3 months before the beginning of the study and committing to it throughout the study - Regular users of very high protection sunscreen products. 2. Related to the disease: - For adults and adolescents: subject with mild to moderate acne with a total of 10 to 40 acne lesions (at least 5 non-inflammatory lesions (open and closed comedones) and at least 3 to 10 inflammatory lesions (papules and pustules) maximum on the face, excluding the nose area), at the inclusion. - Subject prone to have recurrence of acne lesions in autumn (declarative) Exclusion Criteria: 1. Related to the population: - Having participated in another clinical trial within 4 weeks before the inclusion visit and for a longer period if required in the Investigator's opinion Taking part or planning to participate in another clinical trial during the study in the same or another investigation centre - Breastfeeding or pregnant or not willing to take necessary precautions to avoid pregnancy during the study and for at least 3 months before the inclusion visit (for the woman of childbearing potential) - Subject or parent(s)/legal representative(s) deprived of freedom by administrative or legal decision or under guardianship - Subject or parent(s)/legal representative(s) not able to be contacted in case of emergency - Subject admitted in a sanitary or social facility - Subject planning a hospitalization during the study 2. Related to the disease - Cutaneous pathology (psoriasis, atopic dermatitis, skin infectious disease of viral, bacterial, fungus or parasitic origin …) or dermatological condition (especially pityriasis versicolor, severe pigmentation disorders) on the studied zone other than acne liable to interfere with the data of the study - Severe acne - Clinical signs of hormonal disfunctions or hyperandrogenism - Excessive exposure to sunlight or UV-rays within the previous month - Having history of abnormal reactions from exposure to sunlight - Use of self tanning product during the previous month History of hypersensitivity or intolerance to any cosmetic product 3. Related to treatments - Use of a systemic or topical medication with anti-inflammatory or photosensitising products during the previous 2 weeks and for systemic medication with corticoids and/or antihistaminics during the previous 4 weeks - Use of a systemic treatment for acne during the previous month for antibiotics, zinc gluconate and hormonal treatment and during the 6 previous months for isotretinoin - Use of a topical treatment for acne during the previous month (benzoil peroxide, retinoid, antibiotics, azelaic acid…) - Use of anti-acneic or anti-seborrheic cosmestic care (containing alpha hydroxy-acids, retinoic derivatives..) during the 15 previous days - Use of other topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous tolerance and efficacy of the studied product (according to the investigator's appreciation) - Any surgery, chemical or physical treatment on the experimental area within the 12 months prior to the study or foreseeing it for the duration of the study - Woman whose oral contraception is instaured or changed for less than 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
RV4857A
RV4857A formula CD2110 is a sunscreen product

Locations

Country Name City State
Portugal PhD Trials® Lisboa

Sponsors (1)

Lead Sponsor Collaborator
Pierre Fabre Dermo Cosmetique

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the dermatological physical signs The assessment of the dermatological physical signs is based on a visual examination Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Primary Assessment of the dermatological functional signs The functional signs is assessed by questioning the subject Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Primary Assessment of the ophthalmological physical signs The assessment of the ophthalmological physical signs is based on a dermatologist visual examination Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Primary Assessment of the ophthalmological functional signs The functional signs is assessed by questioning the subject Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Primary Assessment of the Tear film Break Up Time (BUT) The tear film break-up time is a test to measure the relative stability of the pre-corneal tear film. This examination is performed by the same Ophthalmologist thanks to a biomicroscope after blinking (using a chronometer). The measured time will be expressed in seconds Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Primary Assessment of global tolerance assessment (dermatogical assesment), a 5-point scale Excellent: no functional nor physical signs related to the investigational product observed or reported by the subjects
Very good
Good
Moderate
Bad
Change from Baseline to 29 and 57 days later
Primary Assessment of global tolerance assessment (ophthalmological assessment), a 5-point scale Excellent: no functional nor physical signs related to the investigational product observed or reported by the subjects
Very good
Good
Moderate
Bad
Change from Baseline to 29 days later
Secondary Change of the number of total acne lesions on the face by counting according to the method of Lucky Change from Baseline to 29, 57 and 85 days later
Secondary Change of the number of non-inflammatory lesions (open and closed comedones) on the face by counting according to the method of Lucky Change from Baseline to 29, 57 and 85 days later
Secondary Change of the number of inflammatory lesions (papules, pustules, nodules) on the face by counting according to the method of Lucky Change from Baseline to 29, 57 and 85 days later
Secondary Assessment of the non-comedogenic potential by statistical comparison of open and closed comedones counted by the investigator on the face before and after 28 days of application of investigational product Change from Baseline to 29 days later
Secondary Change of the acne severity, assess by Global Acne Evaluation (GEA) on a 6-point scale 0: Clear
1: Almost clear
2: Mild
3: Moderate
4: Severe
5 : Very Severe
Change from Baseline to 29, 57 and 85 days later
Secondary Evaluation of the global acne evolution on a 6-point scale -1: Worsening, 0: No change,
Mild improvement,
Moderate improvement,
Good improvement,
Very good improvement
Change from Baseline to 29 and 57 days later
Secondary Evaluation of the global product efficacy by the subjects themselves regarding rebound effect in Autumn Questions Q24 and Q25 at D85 in the self-questionnaire Change from Baseline to 85 days later
Secondary Assessment of the cosmetic acceptability and perceived efficacy of the product The self subject assemsment consists of different questions concerning participants' perception of the product's efficacy (majority of scales ranging from 0 to 10 where 0 was the worst satisfaction and 10 the best one) Change from Baseline to 29 and 57 days later
Secondary To evaluate the impact on Quality of Life of subjects through questionnaires Quality of Life questionnaires consist of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week Change from Baseline to 29 and 57 days later
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Completed NCT04873089 - Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3